Fused ring compound and use thereof in KRAS inhibitor
By developing a new fused ring compound to optimize its structure and pharmacokinetic properties, the problems of low bioavailability and insufficient exposure of existing pan-KRAS inhibitors were solved, and effective inhibition and good pharmacokinetic performance of various KRAS mutants were achieved.
WO2025077770A1 Publication Date: 2025-04-17CHENGDU HYPERWAY PHARM CO LTD +1
13 Cites 18 Cited by
Patent Information
- Application Number
- PCT/CN2024/123898
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-15
- Filing Date
- 2024-10-10
- Publication Date
- 2025-04-17
AI Technical Summary
Technical Problem
The existing pan-KRAS inhibitors have problems with low bioavailability and insufficient exposure, and it is difficult to effectively inhibit various KRAS mutants.
Method used
Develop a new fused ring compound that can effectively inhibit various KRAS mutants by optimizing its structural and pharmacokinetic properties and improving its exposure and bioavailability in the body.
Benefits of technology
This compound can effectively block KRAS activity, has good oral exposure and pharmacokinetic properties, and is suitable for the preparation of drugs used to treat KRAS mutation-related cancers.
✦ Generated by Eureka AI based on patent content.
Abstract
A fused ring compound, a pharmaceutical composition comprising same, and the use thereof. The compound has a structure as represented by formula (I), or is a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a metabolite, a metabolic precursor, an isotope-substituted form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a co-crystal thereof. The compound can be used for treating one or more cancers caused by KRAS mutation.
Need to check novelty before this filing date? Find Prior Art